Co-Diagnostics (CODX) IV at 279 on wide price movement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Co-Diagnostics (CODX) Reports In-Line Q1 EPS, Revenues Beat
May 14, 2020 4:35 PM EDTCo-Diagnostics (NASDAQ: CODX) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $1.55 million versus the consensus estimate of $620 thousand.
Q1 2020 Highlights:
Company commences COVID-19 test sales and reports $1.5 Million of revenue in Q1Gross margins of 71.5% on sales... More